Dermal delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer

J Microencapsul. 2016 Jun;33(4):372-80. doi: 10.1080/02652048.2016.1200150. Epub 2016 Jun 23.

Abstract

Objective: Dermal delivery of Doxorubicin (Dox) would be an ideal way in maximising drug efficiency against skin cancer accompanying with minimising side effects. We investigated the potential of Dox-loaded Solid lipid nanoparticles (SLNs) for topical delivery against skin cancer.

Methods: In vitro and in vivo cytotoxicity of optimised formulation were evaluated on murine melanoma (B16F10) cells by MTT assay and melanoma induced Balb/C mice, respectively. Animal study followed by histological analysis.

Results: Optimised formulation showed mean particle size and encapsulation efficiency (EE) of 92 nm and 86% w/w (0.86% w/w value of encapsulated Dox in the lipid matrix), respectively. FTIR experiment confirmed drug-lipid interaction interpreting the observed high EE value for Dox. In vitro and in vivo results indicated the superiority of cytotoxic performance of Dox-loaded SLN compared to Dox solution.

Conclusion: Our findings may open the possibilities for the topical delivery of Dox to the skin cancerous tissues.

Keywords: SLN; Solid lipid nanoparticles; doxorubicin; melanoma; topical delivery.

MeSH terms

  • Administration, Topical
  • Animals
  • Cell Line
  • Cell Line, Tumor
  • Doxorubicin* / chemistry
  • Doxorubicin* / pharmacokinetics
  • Doxorubicin* / pharmacology
  • Lipids* / chemistry
  • Lipids* / pharmacokinetics
  • Lipids* / pharmacology
  • Melanoma / drug therapy*
  • Melanoma / metabolism
  • Melanoma / pathology
  • Mice
  • Mice, Inbred BALB C
  • Nanoparticles / chemistry*
  • Neoplasms, Experimental / drug therapy*
  • Neoplasms, Experimental / metabolism
  • Neoplasms, Experimental / pathology
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / pathology

Substances

  • Lipids
  • Doxorubicin